CSat Investment Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

CSat Investment Advisory’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$15K	Buy	69 +24	+53%	+$5.27K	0.01%	412
2020 Q4	$11K	Sell	45 -1,428	-97%	-$328K	0.01%	421
2020 Q3	$401K	Buy	1,473 +163	+12%	+$45K	0.04%	192
2020 Q2	$380K	Sell	1,310 -512	-28%	-$139K	0.05%	209
2020 Q1	$434K	Buy	1,822 +489	+37%	+$112K	0.09%	157
2019 Q4	$292K	Sell	1,333 -424	-24%	-$85.8K	0.08%	199
2019 Q3	$298K	Buy	1,757 +240	+16%	+$42.5K	0.09%	177
2019 Q2	$278K	Buy	1,517 +1,481	+4,114%	+$259K	0.1%	166
2019 Q1	$7K	Buy	36 +2	+6%	+$369	﹤0.01%	480
2018 Q4	$6K	Buy	34 +9	+36%	+$1.56K	﹤0.01%	477
2018 Q3	$5K	Sell	25 -5	-17%	-$890	﹤0.01%	473
2018 Q2	$5K	Buy	+30	New	+$4.65K	﹤0.01%	465

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

CSat Investment Advisory's VRTX Position: Q1 2021 in Review

CSat Investment Advisory increased its Vertex Pharmaceuticals (VRTX) stake by 53% in Q1 2021, buying an estimated $5.27K and bringing the position to 69 shares worth $15K. The position accounts for 0.01% of the portfolio, ranked #412.

CSat Investment Advisory first reported a position in VRTX in Q2 2018 and has held it in 12 quarters since. The position peaked at $434K in Q1 2020. 1,000 funds tracked by Wall St. Rank hold VRTX as of Q1 2021.

CSat Investment Advisory held 69 shares of Vertex Pharmaceuticals worth $15K as of Q1 2021.
CSat Investment Advisory bought 24 Vertex Pharmaceuticals shares in Q1 2021, an estimated $5.27K.
Vertex Pharmaceuticals made up 0.01% of CSat Investment Advisory's portfolio in Q1 2021, its #412 holding.
CSat Investment Advisory first reported a position in Vertex Pharmaceuticals in Q2 2018 and has held it in 12 quarters since.
CSat Investment Advisory's Vertex Pharmaceuticals position peaked at $434K in Q1 2020.
1,000 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2021.

Based on CSat Investment Advisory's 13F filing for Q1 2021, filed 13 May 2021.